A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

By Lin Nancy  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1057-1065

Springer Publishing Company

Access to resources Recommend Favorite

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

By Freiwald Matthias   Schmid Ulrike   Fleury Angele   Wind Sven   Stopfer Peter   Staab Alexander  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 759-770

Springer Publishing Company

Access to resources Recommend Favorite

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker

By Lacouture Mario E   Schadendorf Dirk   Chu Chia-Yu   Uttenreuther-Fischer Martina   Stammberger Uz   O'Brien Dennis   Hauschild Axel  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 6, 2013-06 ,pp. : 721-728

Informa Healthcare

Access to resources Recommend Favorite

Diarrhea associated with afatinib: an oral ErbB family blocker

By Yang James Chih-Hsin   Reguart Noemi   Barinoff Jana   Köhler Jens   Uttenreuther-Fischer Martina   Stammberger Uz   O'Brien Dennis   Wolf Jürgen   Cohen Ezra EW  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 6, 2013-06 ,pp. : 729-736

Informa Healthcare

Access to resources Recommend Favorite

Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1)

By Massaccesi Mariangela   Ferro Marica   Cilla Savino   Balducci Mario   Deodato Francesco   Macchia Gabriella   Valentini Vincenzo   Morganti Alessio  

International Journal of Clinical Oncology, Vol. 18, Iss. 5, 2013-10 ,pp. : 784-791

Springer Publishing Company

Access to resources Recommend Favorite